SCHEMBL21552576

SCHEMBL21552576

Cc1ccc(S(=O)(=O)OCCC2CC3(CCCC3)C(=O)N2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
KMT2A Q03164 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
CRBN Q96SW2 1/20 0.33
CASP3 P42574 2/20 0.33
CASP7 P55210 2/20 0.33
STAT3 P40763 1/20 0.32
VDR P11473 1/20 0.32
AKR1B1 P15121 1/20 0.31
CYP2D6 P10635 2/20 0.31
CYP1A2 P05177 1/20 0.31
CASP1 P29466 1/20 0.31
ALDH1A1 P00352 3/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21552575 1.00 CA12 (0.38) CA12CA1CA9KMT2ASMN1; SMN2
SCHEMBL29950335 0.88 CA12 (0.35) CA12CA1CA9KMT2AESR1
SCHEMBL21552671 0.88 CA12 (0.35) CA12CA1CA9KMT2AESR1
SCHEMBL23364110 0.85 ALDH1A1 (0.34) KMT2ASTAT3CYP2D6ALDH1A1CYP2C19
SCHEMBL21552586 0.85 ALDH1A1 (0.34) KMT2ASTAT3CYP2D6ALDH1A1CYP2C19
SCHEMBL21552625 0.85 ALDH1A1 (0.34) KMT2ASTAT3CYP2D6ALDH1A1CYP2C19
SCHEMBL21552642 0.82 CA12 (0.36) CA12CA1CA9KMT2ASMN1; SMN2
SCHEMBL21552535 0.82 CA12 (0.36) CA12CA1CA9KMT2ASMN1; SMN2
SCHEMBL28537628 0.81 GPR119 (0.46) KMT2AMEN1
SCHEMBL28537557 0.81 GPR119 (0.46) KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070907-A1 FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE UNIV TEMPLE (US) 2026-03-12 US disclosed
US-20260070908-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE UNIV TEMPLE (US) 2026-03-12 US disclosed
US-12559494-B2 Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2026-02-24 US disclosed
US-20220306629-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2022-09-29 US disclosed
EP-3790859-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE Temple University - Of The Commonwealth System of Higher Education (US) 2021-03-17 EP disclosed
WO-2019217890-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559494-B2 Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use HTR1B, HTR7, HTR6 CA12 3054/4885CA1 3954/4885CA9 1554/4885
US-20260070907-A1 FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR2C, HTR5A CA12 4303/4885CA1 4226/4885CA9 4004/4885
US-20260070908-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR2C, TPH2 CA12 3619/4885CA1 3779/4885CA9 3171/4885
US-20220306629-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR5A, HTR1A CA12 4591/4885CA1 4441/4885CA9 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.